**Review**

**Therapeutic promise and principles**

**Metabotropic glutamate receptors**

Kenneth Maiese,1–5,* Zhao Zhong Chong,1 Yan Chen Shang1 and Jinling Hou1

1Division of Cellular and Molecular Cerebral Ischemia; 2Departments of Neurology and Anatomy & Cell Biology; 3Barbara Ann Karmanos Cancer Institute; 4Center for Molecular Medicine and Genetics; 5Institute of Environmental Health Sciences; Wayne State University School of Medicine, Detroit, Michigan USA

Key words: Akt, Alzheimer’s disease, amyotrophic lateral sclerosis, apoptosis, β-catenin, erythropoietin, forkhead, Huntington’s disease, metabotropic, oxidative stress, Wnt

For a number of disease entities, oxidative stress becomes a significant factor in the etiology and progression of cell dysfunction and injury. Therapeutic strategies that can identify novel signal transduction pathways to ameliorate the toxic effects of oxidative stress may lead to new avenues of treatment for a spectrum of disorders that include diabetes, Alzheimer’s disease, Parkinson’s disease and immune system dysfunction. In this respect, metabotropic glutamate receptors (mGluRs) may offer exciting prospects for several disorders since these receptors can limit or prevent apoptotic cell injury as well as impact upon cellular development and function. Yet the role of mGluRs is complex in nature and may require specific mGluR modulation for a particular disease entity to maximize clinical efficacy and limit potential disability. Here we discuss the potential clinical translation of mGluRs and highlight the role of novel signal transduction pathways in the metabotropic glutamate system that may be vital for the clinical utility of mGluRs.

**Oxidative Stress and Apoptotic Cell Injury**

A number of mechanisms can account for the degeneration of cells in the body, but the generation of cellular oxidative stress represents a significant component for cell loss in several diseases. Oxidative stress occurs as a result of the development of reactive oxygen species (ROS) that include oxygen free radicals and other chemical entities. Oxygen consumption in organisms, or at least the rate of oxygen consumption in organisms, has intrigued a host of investigators and may have had some of its original origins with the work of Pearl. Pearl proposed that increased exposure to oxygen through an increased metabolic rate could lead to a shortened life span.1 Subsequent work by multiple investigators has furthered this hypothesis by demonstrating that increased metabolic rates could be detrimental to animals in an elevated oxygen environment.2

With current work, oxygen free radicals and mitochondrial DNA mutations have become associated with oxidative stress injury, aging mechanisms, and accumulated toxicity for an organism.3

Oxidative stress is a result of the release of ROS that include superoxide free radicals, hydrogen peroxide, singlet oxygen, nitric oxide, and peroxynitrite.4 Oxygen free radicals and mitochondrial DNA mutations have become associated with tissue injury, aging, and accumulated toxicity for an organism.5,6 Most ROS are produced at low levels during normal physiological conditions and are scavenged by endogenous antioxidant systems that include superoxide dismutase, glutathione peroxidase, catalase, and small molecule substances, such as vitamins C, E, D3 and nicotinamide, the amide form of niacin or vitamin B3.5,61–63

Oxidative stress represents a significant mechanism for the destruction of cells that can involve apoptotic cell injury.6,8–10 It has recently been shown that genes involved in the apoptotic process are replicated early during processes that involve cell replication and transcription, suggesting a much broader role for these genes than originally anticipated.11 Apoptotic induced oxidative stress in conjunction with processes of mitochondrial dysfunction can contribute to a variety of disease states such as diabetes, ischemia, general cognitive loss, Alzheimer’s disease, and trauma.12–16 Oxidative stress can lead to apoptosis in a variety of cell types that involve neurons, endothelial cells (ECs), cardiomyocytes, and smooth muscle cells through multiple cellular pathways.14,17–21

Membrane phosphatidylserine (PS) externalization is an early event during cell apoptosis22,23 and can become a signal for the phagocytosis of cells.10,24,25 The loss of membrane phospholipid asymmetry leads to the externalization of membrane PS residues and assists microglia to target cells for phagocytosis19,26–29 This process occurs with the expression of the phosphatidylserine receptor (PSR) on microglia during oxidative stress,5,30 since blockade of PSR function in microglia prevents the activation of microglia.27,31 As an example, externalization of membrane PS residues occur in neurons during anoxia,32–34 nitric oxide exposure,35,36 and during the administration of agents that induce the production of reactive oxygen species, such as 6-hydroxydopamine.37 Membrane PS externalization on platelets also has been associated with clot formation in the vascular system.38

The cleavage of genomic DNA into fragments39–41 is considered to be a later event during apoptotic injury.42 Several enzymes responsible for DNA degradation have been differentiated and include the...
acidic, cation independent endonuclease (DNase II), cyclophilins, and the 97 kDa magnesium-dependent endonuclease. Three separate endonuclease activities are present in neurons that include a constitutive acidic cation-independent endonuclease, a constitutive calcium/magnesium-dependent endonuclease, and an inducible magnesium dependent endonuclease.

During oxidative stress, mitochondrial membrane transition pore permeability also is increased, a significant loss of mitochondrial NAD+ stores occurs, and further generation of superoxide radicals leads to cell injury. In addition, mitochondria are a significant source of superoxide radicals that are associated with oxidative stress. Furthermore, mutations in the mitochondrial genome have been associated with the potential development of a host of disorders, such as hypertension, hypercholesterolemia, and hypomagnesemia. Reactive oxygen species also may lead to the induction of acidosis-induced cellular toxicity and subsequent mitochondrial failure. Disorders, such as hypoxia, diabetes and excessive free radical production can result in the disturbance of intracellular pH.

Metabotropic Glutamate Receptors (mGluRs) Structure and Functional Role

Glutamate, an excitatory neurotransmitter, plays an important role during both cellular function and cellular injury in the mammalian central nervous system (CNS). Until the mid 1980s, the actions of glutamate in the brain were believed to occur through the activation of glutamate-gated channels termed ionotropic glutamate receptors. Yet, further studies provided evidence for the existence of another family of glutamate receptors that was directly coupled to GTP-binding regulatory proteins. Initial work, such as the observation of glutamate induced phospholipase C generation in neurons, indicated that glutamate had more complex roles that could not be accounted for by only N-methyl-D-aspartate (NMDA), α-aminooxyacetic acid (AMPA), or kainate receptor families. Subsequently, it became evident that a new class of glutamate receptors, termed metabotropic glutamate receptors (mGluRs), was coupled to effector systems through G-proteins (G-proteins).

The first mGluR, now generally termed mGluR1a, was cloned in 1991 by a functional expression screening procedure. Since molecular cloning has preceded pharmacological characterization in the identification of novel mGluRs, the mGluRs are numbered following the order in which their cDNAs have been cloned. G-proteins consist of heterotrimetric proteins that contain three subunits termed α, β and γ. At least forty-six G-proteins have been identified with twenty-seven classified as Gα, five classified as Gβ, and fourteen classified as the Gγ. A variety of heterotrimeric combinations can be formed that may produce a broad spectrum of G-protein signaling. Activation of G-protein-coupled receptors results in the dissociation of the heterotrimer of the G-protein into its α and βγ subunits, which can then bind to a variety of effector molecules. A particular G-protein may be responsible for the modulation of a series of signal transduction pathways. The G-protein βγ has been associated with many effector molecules including adenylate cyclase (AC), phospholipase C-β (PLC-β), mitogen-activated protein kinases (MAPKs), and phosphoinositide 3 kinase (PI 3-K).

G-protein-coupled receptors can be divided into three major subfamilies based on nucleotide and amino acid sequence similarity. Family A consists of the rhodopsin/adrenergic receptors and is characterized by the presence of a restricted number of conserved residues (Asp-Arg-Tyr). Family B consists of peptide hormone and neuropeptide receptors that are characterized by a large extracellular NH2 terminus containing six cysteine residues. Metabotropic glutamate receptors share a common molecular morphology with other G protein–linked receptors. The mGluRs are part of family C of G-protein-coupled receptors, which also includes gamma aminobutyric acid (GABA) receptors and ionotropic calcium receptor transmission. Unlike the other G-protein-coupled receptors families, mGluRs contain a long NH2 terminal chain and couple to G-proteins through their second intracellular loop rather than the third intracellular loop of the receptor.

The mGluRs also are classified into three major groups based on sequence homology, G-protein coupling specificity, and agonist selectivity. Group I mGluRs (including mGluR1 and mGluR5) couple preferentially to Gq to stimulate PLC-β. Activation of PLC-β results in the generation of two second messengers, inositol-1, 4, 5-triphosphate (IP3) and diacylglycerol (DAG), to mobilize intracellular calcium and activate protein kinase C (PKC). Group II mGluRs also can activate AC via coupling to Gs to result in an increase in cAMP. In contrast to group I mGluRs, group II mGluRs (including mGluR2 and 3) and group III mGluRs (including mGluR4, 6, 7, and 8) are negatively coupled to AC to reduce the amount of intracellular cAMP. In addition, activation of group II/III can modulate activity of extracellular signal-regulated protein kinases (ERKs) and PI 3-K (Fig. 1). Yet, different subgroups of the mGluR system may employ pathways of ERKs. For example, group I mGluRs can increase the phosphorylation of ERK2 through PKC. In addition, ERKs may employ phosphorylation of the pro-apoptotic protein Bad and induction of pro-survival gene expression via the cAMP responsive element-binding (CREB) protein dependent pathway to lead to cellular protection. It is not entirely evident whether the protective mechanisms utilized by mGluRs also involve the cellular pathways of the MAP-kinases, since activation of mGluRs does not alter the activity of either p38 or c-Jun N-terminal kinase (JNK), suggesting that protection by mGluRs is independent or below the level of p38 activation.

The G-protein-coupled receptor family is the largest family of cell-surface molecules. These receptors are activated by a wide variety of stimuli, including neurotransmitters, peptides, hormones, growth factors, ions, lipids and light. The mGluR system is one of the principal members in this receptor family and provides an important function as presynaptic auto-receptors that mediate feedback inhibition of glutamate release in a wide variety of brain regions. One of the mechanisms of glutamate inhibition is thought to result from the down-regulation of voltage-activated calcium channels which are necessary for synaptic vesicle exocytosis. The mGluR system also is a critical mediator for the modulation of intracellular signal cascades and physiological function. Interaction among each G-protein subunit, such as –α, –β and –γ subunits, can stimulate effector molecules including adenyllyl/guanosyl cyclases,
 transmission at excitatory synapses onto CA1 pyramidal cells. In addition, group I mGluRs have been shown to alter calcium homeostasis and trigger calcium-sensitive gene transcription in striatal neurons. Group II mGluRs have a significant role in the modulation of GABA afferent inhibition in the ventrobasal thalamus that controls functions of sleep, arousal, and sensation. Both group I and II receptors may be required for the activity-dependent regulation of ribosomes during auditory function. High-frequency stimulation appears to be particularly dependent upon group I and group II metabotropic glutamate receptors. Group III mGluRs have a greater role in motor function through the inhibition of GABA and glutamate transmission in the substantia nigra, pars reticulata, and the periaqueductal grey area.
The ubiquitous distribution of glutamatergic synapses in the nervous system offers a great potential for mGluRs to modulate global CNS function. In the spinal cord, Group I mGluRs can regulate slow excitatory synaptic transmission. In addition, behavioral and physiological studies have demonstrated that mGluRs can regulate fast synaptic transmission, changes in synaptic plasticity, and the modification of the calcium currents. During memory imprinting, group I mGluRs which are juxtaposition to NMDA receptors can modulate the potentiation of NMDA receptor activity to influence both long-term potentiation and long-term depression. Yet, multiple members of the mGluR system may be required for memory formation or memory restoration following an ischemic insult. Activation of mGluRs also can lead to depolarization-induced synapsin I phosphorylation, a process that may be involved in synaptic vesicle exocytosis in visceral sensory neurons. Furthermore, cognitive impairment and psychiatric disease such as with schizophrenia may be tied to mGluR expression and activation.

mGluRs Expression, Progenitor Cell Differentiation and Cell Development

Metabotropic glutamate receptors are expressed throughout the mammalian CNS. In neuronal populations, the mGluR system participates in the processing of cognition, sensory, motor and olfactory information. For example, mGluRs are present in the cerebral cortex, cerebellar neurons, striatal neurons and in the spinal cord. In the hippocampus, a more restricted expression of the receptor subtypes mGluR1b, mGluR2/3, mGluR4a and mGluR5 has been demonstrated. The receptor subtype mGluR4 also has a distinct distribution in the thalamus, hypothalamus, and caudate nucleus. In the retina, mGluR6 is expressed. In contrast, mGluR3 is expressed throughout the brain with dense expression in neurons of the cerebral cortex, caudate-putamen, thalamus, and cerebellum.

The mGluR receptors are distributed in specific subcellular regions and alter their expression during development of the nervous system. During embryonic development, group III mGluRs may prevent the self-renewal of undifferentiated neocortical progenitor cells while group I mGluRs can promote neuroblast proliferation. Group I mGluRs including mGluR1a and mGluR5 predominately exist on the post-synaptic membranes of the glutamatergic synapse junctions. Yet, in the initial postnatal period, mGluR1a and mGluR5 can be found in proximal dendrites and the cell somata. With age, these receptors become densely distributed in the distal part of dendrites to participate in synaptic function. Group II mGluRs (mGluR2/3) are present primarily in astrocytes surrounding the neuronal soma and synapses. A less dense population of group II mGluRs is also located in presynaptic axon terminals. The distribution pattern of mGluR2/3 is believed to be consistently maintained during postnatal development. Of the group III mGluRs, mGluR6 is initially distributed in both the neuronal soma and dendrites in rat retinal bipolar cells, but later redistributes to postsynaptic sites. Presynaptic expression is more common for the mGluR7 subtypes. In group III mGluRs, mGluR4, mGluR6, and mGluR8 also have been identified in microglia and astrocytes. The presence of these receptors in a variety of cell types may be responsible for protection of neuronal cell populations. Redistribution of the expression of mGluRs appears to be necessary for proper nervous system development. For example, redistribution of mGluR6 in rat retinal bipolar cells occurs from somatic and dendritic sites to restricted localization at postsynaptic sites. In the mouse thalamus, subcellular relocalization of group I mGluRs also occurs during postnatal development. In addition to redistribution of receptors, functional changes in the mGluR system also may occur during development. The generation of second messengers, such as cAMP, has been reported to vary under mGluR control during critical periods of ocular dominance and plasticity.

Less information is available for the role of the mGluR system in the vascular system, but new investigations are beginning to provide evidence for a vital function for the mGluR system in brain endothelial cells. Initial work has outlined the expression of mGluRs in cultured rat cerebrovascular ECs and in cardiac cells. Further studies have now demonstrated not only the expression of specific group I mGluRs in cerebral endothelial cells, but also the potential for the mGluR system to protect against apoptotic injury. In addition, mGluR1, mGluR2/3, mGluR4a, mGluR5 and mGluR7 have been demonstrated in the meningeal microvasculature. Interestingly, agents such as nicotine can inhibit the expression of mGluRs in cardiac tissue. More recent studies suggest that activation of mGluRs may control vascular tone.

mGluRs and Disorders of the Nervous and Vascular Systems

mGluRs may be involved in diseases such as diabetes mellitus (DM) which is a significant health concern. Approximately 16 million individuals in the United States and more than 165 million individuals worldwide suffer from DM. By the year 2030, it is predicted that more than 360 million individuals will be afflicted with DM and its debilitating conditions. Type 2 DM represents at least 80% of all diabetics and is dramatically increasing in incidence as a result of changes in human behavior and increased body mass index. Type 1 insulin-dependent DM is present in 5–10% of all diabetics, but is increasing in adolescent minority groups. Furthermore, the incidence of undiagnosed diabetes, impaired glucose tolerance, and fluctuations in serum glucose in the young raises additional concerns. Patients with DM can develop severe neurological and vascular disease that can lead to an increased risk for cognitive decline. As a result, the development of insulin resistance and the complications of DM in the nervous and vascular systems are believed to be, at least in part, a result of cellular oxidative stress. Hyperglycemia can lead to increased production of ROS in endothelial cells, liver and pancreatic β-cells. Recent clinical correlates support these experimental studies to show that elevated levels of ceruloplasmin are suggestive of increased ROS. Furthermore, acute glucose swings in addition to chronic hyperglycemia can trigger oxidative stress mechanisms, illustrating the importance for therapeutic interventions during acute and sustained hyperglycemic episodes.

Several studies highlight the role of mGluRs during cellular metabolism and DM. In animal models of DM, the expression of mGluR1 and mGluR5 messenger RNA are significantly increased in all layers of the dorsal horn of the spinal cord, suggesting that mGluR expression and activity may be associated with the development of diabetic neuropathy. In addition, mGluRs are expressed in pancreatic islet cells and can impact upon the release of glucagon release. For example, the mGlu8 receptor is present in glucagon-secreting
α-cells and intrapancreatic neurons and functions to inhibit glucagon release. Additional work has shown that mGluR3 activation can protect neurons from glucose related oxidative stress as well as prevent apoptotic injury in vascular cells.

In regards to other disorders, the modulation of the mGluR system has been proposed for the treatment of bipolar disease since these receptors may modulate signal transduction during affective disorders. Furthermore, more recent work in animal models suggests that Group III mGluRs may be beneficial for the treatment of psychosis. For diseases such as trisomy 21, a congenital disorder with mental impairment, enhanced expression of the mGluR subtype 5 has been reported. Additionally, dysfunctional signaling in the Group I mGluR system may be responsible for other types of abnormal cognitive development found in disorders such as fragile X mental retardation caused by the lack of fragile X mental retardation protein (FMRP).

In progressive disorders such as amyotrophic lateral sclerosis (ALS), the mGluR1a receptor may be endogenous cellular protection, since surviving motor neurons from the spinal cord of ALS patients maintain mGluR1a at levels comparable to that from controls. Yet, other work indicates that mGluR inhibition may be required to protect neurons during ALS. In epilepsy, group I mGluR activation can lead to prolonged epileptiform discharges and enhanced expression of group II and III metabotropic receptors in the hippocampus of patients with epilepsy has been observed. However, some work supports a protective role for mGluRs in epilepsy, since activation of group II mGluRs has been shown to prevent seizures in experimental animal models. Furthermore, recent work illustrates that disruption between the mGluR7a receptor and its PDZ-interacting protein, protein interacting with C kinase 1 (PICK1), can result in behavioral changes and EEG recordings consistent with absence epilepsy, suggesting that maintenance of mGluR function can protect against epileptic disorders in some scenarios. Reported abnormal expression of mGluR1 also has been reported in Pick’s disease. Modulation of synaptic and receptor activity by mGluRs during other chronic neuronal disorders, such as in Huntington’s disease, has recently been suggested to alter cellular susceptibility to injury. In particular, huntingtin protein, which is associated with excitotoxic death of striatal neurons, can lead to the desensitization of mGluR1 that may promote cell death. Changes in expression patterns of group III mGluRs also have been observed during inflammatory disorders, such as multiple sclerosis, and during acute central or peripheral nerve trauma.

mGluRs also appear to have a role in Parkinson’s disease (PD). For example, mGluRs have been associated with the basal ganglia synaptic transmission through several mechanisms. Increased binding of mGluR5 in the striatum of parkinsonian primates has been demonstrated with PET scanning. Activation of group I mGluRs can invoke excitatory postsynaptic current in dopaminergic neurons, facilitate dopamine release from nigrostriatal terminals and modulate GABA release. In addition, group I mGluR activation can prevent amphetamine-induced rotational behavior in the unilateral 6-hydroxydopamine (6-OHDA) lesion rat model of PD. These results suggest that group I mGluRs agonists may have a therapeutic potential in PD. Yet, group I mGluRs in the subthalamic nucleus appear also to increase the excitation output in the basal ganglia. Group I mGluRs (mGluR5) can lead to an excitatory drive in subthalamic nucleus neurons. More specifically, stimulation of striatal group I mGluRs inhibits striatal projection neuronal activity, while stimulation of subthalamic metabotropic glutamate receptors increases subthalamic nucleus activity.

Another consideration for PD is the involvement of group II mGluRs. Group II mGluRs are presynaptically localized on subthalamic nucleus terminals. Activation of these receptors inhibits excitatory transmission at subthalamic nucleus synapses. As a result, selective agonists of group II mGluRs can reduce excitatory drive through an indirect pathway, which is enhanced in PD, and provide a different approach to the treatment of PD. For example, in a haloperidol-induced rat model of PD, a selective agonist of group II mGluRs, LY354740 ((+)-2-aminobicyclo[3.1.0.]hexane-2,6-dicarboxylic acid), has been demonstrated to reverse parkinsonian muscle rigidity and catalepsy. In another model of PD through application of reserpine in rats, the parkinsonian akinesia was relieved by injection of the group II mGluR receptor agonist, (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine. In addition, group II mGluR receptor agonists may protect through the release of trophic factors or potentially modulate extracellular glutamate uptake. Taken together, agonists for group II mGluRs may be promising agents in the management of PD.

Group III mGluRs also play an important role in synaptic transmission in basal ganglia circuits. Of these, mGluR7 is presynaptically localized in the striatum, the globus pallidus, and the substantia nigra pars reticulata (Kosinski et al., 1999) and modulates synaptic transmission through direct and indirect pathways. Activation of mGluR7 inhibits GABA as well as glutamate transmission in the substantia nigra pars reticulata. As a result, modulation of excitatory and inhibitory synaptic transmission by mGluR7 may yield no alteration in the output of the substantia nigra pars reticulata. In contrast to mGluR7, mGluR4 appears to be more selectively localized in striatopallidal synapses and inhibits synaptic activity. Consequently, the selective agonists for mGluR4 may provide an alternate therapy for the treatment of PD.

In addition to PD, other neurodegenerative disorders such as Alzheimer’s disease (AD) have been linked to mGluRs. AD is characterized by two pathologic hallmarks that consist of extracellular plaques of amyloid-β peptide aggregates and intracellular neurofibrillary tangles composed of hyperphosphorylated microtubular protein tau. The amyloid deposition that constitutes the plaques is composed of a 39-42 amino acid peptide (Aβ), which is the proteolytic product of the amyloid precursor protein (APP). Large soluble fragments (APPs) that are the result from the cleavage of APP within its Aβ domain are secreted into the extracellular medium. Overexpression of APP can accelerate Aβ secretion which can form insoluble amyloid aggregates contributing to the development of AD. In AD, a downregulation of mGluR binding sites occurs. In addition, group I mGluRs are desensitized in the frontal cortex in AD patients and these modifications have been correlated with the progression of AD. Other work has shown that mGluR antagonists may control Aβ synaptic transmission. Interestingly, postsynaptic FMRP binds to and regulates the translation of amyloid precursor protein (APP) mRNA through metabotropic glutamate receptor activation to suggest a link between fragile X syndrome and AD.
Metabotropic receptors also have been coupled to the acceleration of APP processing. Activation of mGluR1 in human glioma and neuroblastoma cells favors the processing of APP into nonamyloidogenic APPs resulting in the reduction of Aβ formation and an alteration in APP secretion. In hippocampal neurons, the release of APPs also is accelerated by stimulation of mGluRs, but not with ionotropic glutamate receptors. In brain cortical and hippocampal slices, the stimulation of group I and group II mGluRs by trans-(1S,3R)-1-amino-1,3-cyclopentane dicarboxylic acid (ACPD) can increase the release of APPs. The process can be blocked by the administration of (±)-α-methyl-4-carboxyphenylglycine, a non-selective antagonist of group I and group II mGluRs.

The regulation of APP processing by mGluRs also appears to be dependent on the activation of protein kinase C (PKC). PKC consists of a family of serine-threonine kinases that are physiologically activated by a number of lipid cofactors and are considered to be important transducers in several agonist-induced signaling cascades. In the PKC family, at least 12 distinct serine/threonine kinase isoenzymes that have important actions in transmembrane signal transduction pathways regulating cell proliferation, differentiation, cytoskeletal functions, gene transcription, apoptosis, and drug resistance exist. Activation of PKC may be either pro-apoptotic or anti-apoptotic depending on the cell type. Studies have begun to define isomform-specific functions of PKC in the apoptotic pathway and the alterations of specific PKC isozymes during injury. For example, PKC forms that appear to be anti-apoptotic include PKC-α, PKC-βII, and PKC-ε and the atypical isotypes PKC-λ and PKC-ζ. During free radical exposure or anoxia, activation of mGluRs has been shown to protect neurons through pathways that can modulate PKC. Neuroprotection by the subtypes mGluR1a, mGluR2, and mGluR5 appears to be dependent on the direct modulation of PKC activity. Furthermore, PKC may be able to phosphorylate mGluRs and lessen activation of these receptors. In regards to AD, inhibition of PKC activity can block alterations in secretion of APPs in response to the activation of mGluRs.

Of equal importance to the functional preservation of cells during neurodegenerative processes is the role of mGluRs during cellular inflammation. In particular, one can consider the role of microglia in the brain that can lead to the phagocytic removal of both neurons and vascular cells. During inflammation, microglial cells require the activation of intracellular cytotoxic pathways to proliferate and remove injured cells. Subsequently, microglia can form a barrier for the removal of foreign microorganisms from the CNS and promote tissue repair during neuronal and vascular cell injury. Yet, microglia also may lead to cellular damage through the generation of reactive oxygen species and the production of cytokines. Furthermore, microglial activation has been correlated with several neurodegenerative disorders that include AD with the co-localization of microglia and amyloid plaque development.

Given the impact that inflammatory cells may have upon the progression or resolution of degenerative insults throughout the body, it becomes essential to consider whether mGluRs can control inflammatory pathways. In regards to mGluRs, activation of group I mGluRs can prevent neuronal membrane PS exposure and inhibit microglial activation by decreasing the expression of proliferating cell nuclear antigen (PCNA) and uptake of bromodeoxyuridine (BrdU) in microglia. Activation of group I mGluRs can block neuronal PS exposure and prevented subsequent neuronal cell engulfment by microglia seeking neurons with PS externalization. However, other subgroups of mGluRs may invoke a different response with microglial activation during cell injury. For example, during ischemic stroke in an animal model, activation of group II mGluRs may lead to microglial release of tumor necrosis factor-α (TNF-α) that can be toxic to neurons.

**mGluRs and Novel Signal Transduction Pathways**

**Protein kinases.** Several cellular signal transduction pathways may impact upon the ultimate biological function of mGluRs. For example, the phosphatidylinositol 3-kinase (PI 3-K) pathway through protein kinase B (Akt) can determine cytoprotection through mGluRs. Phosphorylation of Akt by mGluRs leads to its activation and protects against genomic DNA degradation and membrane PS exposure. Upregulation of Akt activity during multiple injury paradigms, such as with matrix detachment, neuronal axotomy, N-methyl-D-aspartate toxicity, hypoxia, β-amyloid toxicity, and oxidative stress increases cell survival. Also can also directly control microglial activation through the prevention of Bcl-xL degradation and the inhibition of caspase 1-, 3-, and 9-like activities. Activation of Akt by mGluRs also may contribute to new dendritic cell growth and protein synthesis in neurons. These observations are thought provoking since Akt is closely associated with a number of trophic factors such as erythropoietin (EPO). The ability of EPO to enhance cell survival during injury can depend upon the PI 3-K pathway through protein kinase B (Akt). Akt may be an essential component for EPO protection especially during disease processes such as diabetes, since inhibition of Akt activity blocks cellular protection and anti-inflammatory mechanisms by EPO. EPO has been shown to employ the PI 3-K/Akt pathway in a variety of experimental models of injury. Cytoprotection in these models can involve transcription factor regulation, maintenance of ΔΨm, prevention of cytochrome c release and blockade of caspase activity.

Experimental studies have demonstrated that mGluRs can increase cellular survival during injury paradigms through the activation of the PI 3-K/Akt pathways (Fig. 1). In rat hippocampal neuronal cultures, application of the group I mGluR agonists prevent neuronal injury during oxidative stress through increased Akt activity. In addition, Akt activation through mGluRs may protect against amyloid toxicity. This enhancement of Akt activity by mGluR1 may proceed through the formation of a complex that includes Homer, an adaptor protein, and PI 3-K to prevent neuronal apoptosis. As a second possible protective mechanism, mGluR inhibition of caspase 3-like activity may serve to prevent the caspase 3 mediated cleavage of Akt and foster increased cellular survival through a prolonged half-life of Akt. Furthermore, regulation of Akt activity appears closely linked to memory formation that involves mGluRs. Interestingly, mGluRs, such as mGluR1α, can lose the ability to be cytoprotective and activate Akt during NMDA receptor activation that may lead to the calpain-mediated truncation of mGluR1α.

In addition to Akt and PKC that have been previously discussed, protein kinase A (PKA) is another potential pathway that may offer...
control of synaptic plasticity as well as cytoprotection through the mGluR system (Fig. 1). The mGluR system employs PKA activation for the regulation of memory retrieval long-term depression. In addition, postsynaptic depolarization of Purkinje neurons in the rat cerebellar cortex that leads to long-term potentiation of GABA receptor responsiveness termed rebound potentiation requires both mGluR1 and PKA. During paradigms of cellular injury, activation of PKA can prevent apoptosis in a number of cell types, including neurons, neutrophils, and smooth muscle cells. In addition, loss of PKA activity during toxic insults can lead to cell injury. Protection by PKA is believed to reside upstream from the inhibition of caspase 3-like activity. Furthermore, PKA has been shown to phosphorylate Bad, a member of Bcl-2 protein family, which can prevent the induction of cell injury. In the mGluR system, the subtype mGluR4 requires the activation of PKA to prevent cellular injury following acute neurodegenerative insults.

**Forkhead transcription factors**. Several other novel pathways that may determine the cytoprotective capacity of mGlurRs during oxidative stress are linked to Akt. For example, Akt is a central regulatory element for the mammalian forkhead transcription factor family that oversees processes that can involve cell metabolism, cell development, and apoptosis. Over one hundred forkhead genes and 19 human subgroups that range from FOXA to FOXS are now known to exist since the initial discovery of the fly Drosophila melanogaster gene forkhead. In particular, members of the mammalian forkhead transcription factors of the O class (FoxOs), FoxO1, FoxO3, FoxO4 and FoxO6, have emerged as important targets in the neuronal and vascular systems since they can modulate processes associated with angiogenesis, stem cell proliferation, cardiovascular injury, tumorigenesis, and vascular cell longevity. Forkhead proteins function as transcription factors to either inhibit or activate target gene expression. These proteins bind to DNA through the forkhead domain that relies upon fourteen protein-DNA contacts. Post-translational modification of forkhead proteins, such as phosphorylation or acetylation, alters the binding to DNA to prevent transcriptional activity. However, other mechanisms may influence DNA binding of forkhead proteins, such as variations in the N-terminal region of the DNA recognition helix, changes in electrostatic distribution, and the ability of forkhead proteins to be shuttled to the cell nucleus. Akt can phosphorylate and inactivate FoxO1, FoxO3a and FoxO4, FoxO6, have emerged as important targets in the neuronal and vascular systems since they can modulate processes associated with angiogenesis, stem cell proliferation, cardiovascular injury, tumorigenesis, and vascular cell longevity. Forkhead proteins function as transcription factors to either inhibit or activate target gene expression. These proteins bind to DNA through the forkhead domain that relies upon fourteen protein-DNA contacts. Post-translational modification of forkhead proteins, such as phosphorylation or acetylation, alters the binding to DNA to prevent transcriptional activity. However, other mechanisms may influence DNA binding of forkhead proteins, such as variations in the N-terminal region of the DNA recognition helix, changes in electrostatic distribution, and the ability of forkhead proteins to be shuttled to the cell nucleus.

Akt can phosphorylate and inactivate FoxO1, FoxO3a and FoxO4. During oxidative stress, Akt can prevent cellular apoptosis through the phosphorylation of FoxO proteins. Post-translational phosphorylation of FoxO proteins maintain FoxO transcription factors in the cytoplasm by association with 14-3-3 proteins and prevent the transcription of pro-apoptotic target genes. An exception in regards to the subcellular trafficking of FoxO proteins involves FoxO6. This FoxO protein usually resides in the nucleus of cells and is phosphorylated by Akt in the nucleus. Activation of Akt also controls the apoptotic pathways of the caspase family that may offer an alternative mechanism to regulate FoxO proteins. The caspases 1 and 3 have each been linked to the apoptotic pathways of genomic DNA cleavage, cellular membrane PS exposure, and activation of inflammatory cells. Caspase pathways may be tied to the forkhead transcription factor FoxO3a since increased activity of FoxO3a can result in cytochrome c release and caspase-induced apoptotic death. Pathways that can inhibit caspase 3 activity appear to offer a unique regulatory mechanism. For example, caspase 3 cleavage of FoxO3a can lead to pro-apoptotic amino-terminal (Nt) fragments that can lead to cell death. However, during caspase 3 inhibition, inactive phosphorylated FoxO3a remains intact and does not lead to apoptotic cell injury during oxidative stress.

During periods of oxidative stress, FoxO transcription factors can lead to cell injury and apoptosis, since forkhead transcription factors such as FoxO1 and FoxO3a must be present for oxidative stress to result in apoptotic cell injury. In addition, FoxO3a in conjunction with c-Jun N-terminal kinase (JNK) has been shown to modulate an apoptotic ligand activating a Fas-mediated death pathway in cultured motoneurons, to lead to apoptosis through tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) and BH3-only proteins Noxa and Bim in neuroblastoma cells and to promote pro-apoptotic activity of p53. These studies correlate well with experimental work demonstrating that protein inhibition or gene knockdown of FoxO1 or FoxO3a can result in stroke reduction, enhance pancreatic β-cell or neuronal survival through NAD+ precursors during oxidative stress and provide trophic factor protection in the cardiovascular system with EPO and neurotrophins. However, some studies suggest that the loss of FoxO1, FoxO3a and FoxO4 protein expression may actually lead to an increase in free radical release that can be responsible for oxidative stress.

In relation to mGlurRs, inhibition of FoxO3a activity appears to be required to mediate cellular protection during oxidative stress (Fig. 1). During oxidative stress in primary hippocampal neurons, free radical exposure can increase the phosphorylation of FoxO3a within 6 hours, but over the course of a 12 hour period the expression of phosphorylated and total FoxO3a is lost, suggesting its destruction. In contrast, activation of the mGluR1 receptors maintains inhibitory phosphorylation of FoxO3a over both a 6 and 12 hour period to block FoxO3a activation. Furthermore, prevention of phosphorylated and total FoxO3a degradation by mGluR1 activation may assist with neuronal cytoprotection by inhibiting the formation of Nt fragments. The subsequent proteolysis of phosphorylated and total FoxO3a can lead to the generation of apoptotic amino-terminal (Nt) fragments.

The proteolytic processing of FoxO3a also is linked to the induction of caspase 3 activity. FoxO3a has been shown to be a substrate for caspase 3-like proteases at the consensus sequence DELD304A (Fig. 1). Blockade of caspase 3-like activity prevents the destruction of phosphorylated FoxO3a in neurons during free radical exposure. Yet, inhibition of caspase 9-like activity does not offer a similar level of prevention for the degradation of phosphorylated FoxO3a since FoxO3a has a consensus sequence specific for caspase 3. Some protection by caspase 9 inhibition against FoxO3a degradation could be expected since caspase 3 activation is dependent upon initial caspase 9 activation. The results correlate well with other reports that illustrate that mGlur1 receptor activation can prevent caspase 3 and caspase 9 activity and that activation of group III mGlurS prevent caspase 3 activity during amyloid toxicity, suggesting that the mGlur receptors are able to block the degradation of FoxO3a as a result of the inhibition of caspase activity.

β-catenin, glycogen synthase kinase-3β and calcium pathways. FoxO proteins are associated with additional pathways that modulate...
The Wnt proteins are secreted cysteine-rich glycosylated proteins that can control cell proliferation, differentiation, survival, and tumorigenesis. More than eighty target genes of Wnt signaling pathways have been demonstrated in human, mouse, Drosophila, Xenopus and zebrafish. These genes are present in several cellular populations, such as neurons, cardiomyocytes, endothelial cells, cancer cells and pre-adipocytes. At least nineteen of twenty-four Wnt genes that express Wnt proteins have been identified in the human, mouse, Xenopus embryos and to activate certain signaling cascades that consist of the Wnt1 class and the Wnt5a class. One Wnt pathway involves intracellular calcium release and is termed the non-canonical or Wnt/calcium pathway consisting primarily of Wnt4, Wnt5a and Wnt11. The non-canonical system functions through non-β-catenin-dependent pathways and also includes the planar cell polarity (PCP) pathway or the Wnt-calcium-dependent pathways. A second pathway controls target gene transcription through β-catenin, generally referred to as the canonical pathway that involves Wnt1, Wnt3a and Wnt8.

The β-catenin pathway ties FoxO proteins and Wnt signaling together. For example, in relation to Alzheimer's disease, amyloid is toxic to cells and is associated with the phosphorylation of FoxO1 and FoxO3a that can be blocked with ROS scavengers. A common denominator in the pathways linked to amyloid toxicity involves Wnt signaling through β-catenin. β-catenin may increase FoxO transcriptional activity and competitively limit β-catenin interaction with members of the lymphoid enhancer factor/T cell factor family and β-catenin also has been demonstrated to be necessary for protection against amyloid toxicity in neuronal cells. With the mGluR system, activation of group I mGluRs can modulate the phosphorylation of β-catenin and its intracellular translocation from the cytoplasm to the cell nucleus (Fig. 1). During oxidative stress, phosphorylation of β-catenin is increased that can lead to its degradation and subsequent cell injury, but group I mGluR activation blocks phosphorylation of β-catenin within 6 hours following free radical exposure. The blockade of β-catenin phosphorylation is associated with its translocation from the cytoplasm to the nucleus to allow it to assist with known cytoprotective pathways. In addition, the ability of mGluR activation to control the phosphorylation and activity of β-catenin has been shown to be dependent upon Akt1, since gene silencing of Akt1 expression leads to phosphorylation of β-catenin during oxidative stress.

Glycogen synthase kinase-3β (GSK-3β) also plays a role in these pathways, since Wnt binds to its receptors and the co-receptor low-density lipoprotein receptor-related protein 5/6 (LRP-5/6) to inhibit GSK-3β. Pathways that block GSK-3β activity such as through Wnt appear to be critical for neuronal protection. For example, the neuroprotective attributes of Wnt1 against β-amloid toxicity are lost during gene silencing of Wnt1 protein expression. More importantly, Wnt 1 protection is dependent upon Akt activity and the inhibition of GSK-3β with the cellular translocation β-catenin to the nucleus 240. Modulation of GSK-3β activity also can regulate progenitor cell proliferation and differentiation, promote midbrain differentiation, control cardiac hypertrophy, and increase cell survival during oxidative stress, such as during neurofibrillary pathology and cardiac injury. GSK-3β activity also can influence inflammatory cell survival and activation. As a result, GSK-3β is considered to be an important treatment strategy for several degenerative disorders. Recently, additional work has shown that mGluR activation blocks GSK-3β activity to promote translocation of β-catenin to the nucleus through an Akt dependent mechanism (Fig. 1).

Other Wnt pathways also pertain to the control of intracellular calcium (Ca²⁺) release. These involve the non-canonical or Wnt/Ca²⁺ pathway consisting primarily of Wnt4, Wnt5a and Wnt11 that functions through non-β-catenin-dependent pathways and also include the planar cell polarity (PCP) pathway or the Wnt-calcium-dependent pathways. A second pathway controls target gene transcription through β-catenin, generally referred to as the canonical pathway that involves Wnt1, Wnt3a and Wnt8.

Interestingly during the development of the nervous system, G-protein signaling with the mGluR system is required for the modulation of intracellular calcium homeostasis. Immature and developing neurons require higher intracellular calcium concentrations than their mature counterparts to facilitate neuronal survival, synapse formation, dendrite growth, and other cellular functions. As a result, the modulation of intracellular calcium by the mGluR system has proven to be necessary for neuronal development, such as in the cochlear nucleus magnocellular neurons and in maturing hippocampal neurons. Furthermore, group I mGluR1 facilitates L-type voltage-dependent calcium channels currents through PKC and group II mGluRs can control calcium flux in the suprachiasmatic nucleus that may oversee circadian function. In astrocytes, both group I and group II mGluRs have been associated with the generation of calcium oscillations.

Modulation of intracellular calcium by the mGluR system also may be vital for cytoprotection (Fig. 1). For example, preservation of cellular energy reserves during oxidative stress is dependent upon the maintenance of mitochondrial integrity. Group I mGluRs can preserve mitochondrial membrane potential in endothelial cells and neurons and prevent cell injury during oxidative stress. The precise mechanisms by which the mGluRs employ to preserve mitochondrial integrity are not clear, but may involve the modulation of intracellular calcium stores and intracellular pH. Reduction in mitochondrial intracellular calcium stores and free radical generation has been suggested to promote the maintenance of mitochondrial membrane potential and integrity. Activation of group I mGluRs can regulate the release of intracellular calcium from both Ins (1,4,5) P3-sensitive and ryanoidine-sensitive calcium stores. In addition, group I mGluRs can modulate free radical signal transduction cascades in both neuronal and endothelial cell populations. Furthermore, intracellular acid-base levels may be involved in these protective mechanisms since calcium as well as pH control cellular endonuclease activity. For example, activation of mGluRs prevents cellular injury through the modulation of endonuclease activity that is linked to changes in intracellular pH.

Considerations for the Future

As members of the broad G-protein receptor family, mGluRs play a diverse role in multiple processes that include cell development, cell signaling, and cell survival. Effective treatment for a
number of disease entities such as amyotrophic lateral sclerosis, psychiatric disease, Parkinson’s disease, and Alzheimer’s disease may ultimately rely upon mGluR modulation and targeting novel signal transduction pathways of metabotropic receptors during oxidative stress. In particular, pathways tied to Akt, forkhead transcription factors, β-catenin, and intracellular calcium release may prove to be vital for the development of new therapeutic strategies.

Yet, the role of the mGluR activation during cell injury is not always clear and can differ among cell systems. In models of demyelinating disease, only activation of specific mGluRs has the capacity to protect oligodendrocyte progenitor cells. However, downregulation of the mGluR system following spinal cord injury during both pharmacological and in situ has been suggested to lead to the generation of post-injury pain subsequently improve neuronal survival. Acute versus chronic therapeutic efficacy. In a rat model of PD, it is chronic rather than acute treatment with a mGluR5 antagonist that can reverseakinetic deficits. Furthermore, changes in the cellular environment, such as decreased intracellular calcium release, may allow antagonism of the mGluR system to exert cytoprotection. In addition, the nature and extent of the cellular injury may determine whether activation or inhibition of the mGluR system is ultimately required for cellular protection. Since the role mGluRs play in the body is not straightforward, future investigations are necessary to further define the unique signal transduction pathways controlled by the metabotropic system for the effective translation of mGluRs into new therapeutic avenues.

Acknowledgments

We apologize to our colleagues whose work we were unable to cite as a result of article space limitations. This research was supported by the following grants (K.M.): American Diabetes Association, American Heart Association (National), Bugher Foundation Award, Janssen Neuroscience Award, LEARN Foundation Award, MI Life Sciences Challenge Award, Nelson Foundation Award, NIH NIEHS (P30 ES06639), and NIH NINDS/NIA.

References

1. Pearl R. The rate of living. University of London Press, London 1928.
2. Muller FL, Lustgarten MS, Jang Y, Richardson A, Van Remmen H. Trends in oxidative aging theories. Free Radic Biol Med 2007; 43:477-503.
3. Yiu R, Matsura ET. Detection of deletions flanked by short direct repeats in mitochondrial DNA of aging Drosophila. Mutat Res 2006; 594:155-61.
4. Chong ZZ, Maiese K. The Sdc homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22:1251-67.
5. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol 2006; 21:103-24.
6. Maiese K, Li F, Chong ZZ, Shang YC. The Wnt signaling pathway: Aging gracefully as a protectionist? Pharmacol Ther 2008; 118:58-81.
7. Regulska M, Leskiwicz W, Budziszewska B, Kutner A, Janatas D, Basta-Kaim A, Kubera M, Jaworska-Feil L, Lason W. Inhibitory effects of 1,25-dihydroxyvitamin D(3) and its low-calcemic analogues on staurosporine-induced apoptosis. Pharmacol Rep 2007; 59:393-401.
8. Chong ZZ, Li F, Maiese K. Attempted Cell Cycle Inhibition in Post-Mitotic Neurons Occurs in Early and Late Apoptotic Programs Through Rh, E2F1, and Caspase 3. J Neurosci Res 2006; 83:25-39.
9. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer’s drug memantine. J Biol Chem 2007; 282:11590-601.
10. Lin SH, Maiese K. The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. J Cereb Blood Flow Metab 2001; 21:262-75.
11. Cohen SM, Cordeiro-Stone M, Kaufman DG. Early replication and the apoptotic pathway. J Cell Physiol 2007; 213:434-9.
12. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005; 79:207-46.
13. Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer’s disease. Brain Res Brain Res Rev 2005; 49:1-21.
14. Harris SE, Fox H, Wright AF, Hayward C, Starr JM, Whalley LJ, Deary IJ. A genetic association analysis of cognitive ability and cognitive ageing using 325 markers for 109 genes associated with oxidative stress or cognition. BMC Genet 2007; 8:43.
15. Leunen K, Hauptmann S, Abdel-Kader R, Scherpig I, Keil U, Stroesenzajder JB, Eckert A, Muller WE. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer’s disease? Antioxid Redox Signal 2007; 9:1659-75.
16. Okouchi M, Ekshyoun O, Maracine M, Aw TY. Neuronal apoptosis in neurodegeneration. Antioxid Redox Signal 2007; 9:1059-96.
17. Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-3(L) and caspase 1, 3, and 9. Exp Cell Res 2004; 296:196-207.
18. Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3β and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007; 19:263-72.
19. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt in the modulation of apoptotic phosphatidylyserine exposure and microglial activation. Mol Pharmacol 2003; 64:557-69.
20. Karunakaran S, Divakar L, Saeed U, Agarwal V, Svanidzian R, Ravindranath V. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson’s disease: protection by alpha-lipoic acid. Free J 2007; 21:2226-36.
21. Verdaguer E, Susana Gde A, Clemens A, Pallas M, Camins A. Implication of the transcription factor E2F1 in the modulation of neuronal apoptosis. Biomed Pharmacother 2007; 61:399-09.
22. Maiese K, Vincent A, Lin SH, Shaw T. Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2002; 70:262-75.
23. Maisi K, Vincent A, Lin SH, Shaw T. Group I and Group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2002; 70:262-75.
24. Chong ZZ, Kang J, Li F, Maiese K. mGluR Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways. Curr Neurovasc Res 2005; 2:197-211.
25. Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3β, beta-catenin, and nuclear factor-kappaB. J Neurovasc Res 2006; 3:187-201.
26. Chong ZZ, Kang JQ, Maiese K. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol Histopathol 2003; 18:173-89.
27. Kang JQ, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cytosine protease activity. J Neurosci Res 2003; 74:37-51.
28. Maiese K, Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 2003; 24:228-32.
29. Mallat M, Marin-Teva J, Chetrit C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 2005; 15:101-7.
30. Li F, Chong ZZ, Maiese K. Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD(+) Precursor Nicotinamide. Curr Med Chem 2006; 13:883-95.
31. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003; 138:1107-18.
32. Maiese K. The dynamics of cellular injury: transformation into neuronal and vascular protection. Histol Histopathol 2001; 16:633-44.
33. 2001; 3:187-201.
34. 2001; 16:633-44.
35. 2001; 47:661-72.
35. Chong ZZ, Lin SH, Kang JQ, Maiese K. The tyrosine phosphatase SHPF2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell Mol Neurobiol 2003; 23:317-28.
36. Maiese K, TenBroeke M, Kue I. Neuroprotection of luteolus is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997; 68:710-4.
37. Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, Cuadrado A. Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem 2002; 278:13899-904.
38. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J, Thorin-triggered platelet apoptosis. J Thromb Haemost 2004; 4:2656-63.
39. Maiese K, Ahmad I, TenBroeke M, Gallant J. Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. J Neurosci Res 1999; 55:472-85.
40. Albert PR, Robillard L. G protein specificity. Traffic direction required. Cell Signal 2002; 14:393-400.
41. Maiese K, Vincent AM. Critical temporal modulation of neuronal programmed cell injury. J Cell Physiol 2000; 183:238-40.
42. Maiese K, Vincent AM. Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. J Neurosci Res 2000; 59:568-80.
43. Chong ZZ, Kang JQ, Maiese K. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid Redox Signal 2004; 6:277-87.
44. Vincent AM, Maiese K. Nitric oxide induction of neuronal endocytosis activity in programmed cell death. Exp Cell Res 1999; 246:290-300.
45. Vincent AM, TenBroeke M, Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endocytosis activity and intracellular pH. Exp Neurol 1999; 155:79-94.
46. Saito H, Klimo P, Quayle AM, Brown NJ, Lee WM. Metabolic decompensation in children with type 1 diabetes mellitus associated with oxidative stress. J Cereb Blood Flow Metab 1997; 17:207-17.
47. Albert PR, Robillard L. G protein specificity. Traffic direction required. Cell Signal 2002; 14:393-400.
48. Francesconi A, Davison RM. Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. J Biol Chem 1998; 273:5615-24.
49. Katsu Y, Mikoshiba K. Pharmacological and immunocytochemical characterization of metabotropic glutamate receptors in cultured Purkinje cells. J Neurosci 1992; 12:4253-63.
50. Fadok VA, Schraufstatter IU, Schleider F, Curns K, Bocken J. Characterization of a metabotropic glutamate receptor: direct negative coupling to adenylyl cyclase and inhibition of adenylate cyclase activity in striatal slices. J Neurosci Res 1997; 45:841-50.
51. Matsuyama T, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S. Sequence and expression of a metabotropic glutamate receptor: direct negative coupling to adenylyl cyclase and inhibition of adenylate cyclase activity in striatal slices. J Neurosci Res 1997; 45:841-50.
52. Price KN, Nicholsock LM, Klauber MP. Postsynaptic Induction and Presynaptic Expression of Two Distinct Metabotropic Glutamate Receptor Subtypes in the Rat Basolateral Amygdala. J Neurophysiol 2002; 88:2044-51.
53. Plessis-Ashard M, Allard C. Calcium signaling in the developing dorsal horn following traumatic injury. Neuroreport 1999; 10:3861-7.
54. Fiore FA, Dallamora S, Picard M, Kandler K. Glutamate receptor calcium responses in the adult rodent cerebellum. Neuroreport 1999; 10:3861-7.
55. Ito N, Bartunek J, Spitzer KW, Lorell BH. Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes. Circulation 1997; 96:23-30.
56. Anwyl R. Metabotropic glutamate receptors: evidence for target selectivity. J Neurochem 2002; 80:278-98.
57. Sladeczek F, Pin J-P, Recasens M, Bockaert J, Weiss S. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature (Lond) 1985; 317:717-9.
58. iducci A, Duvoisin RM. Role of the second and third intracellular loops of metabotropic glutamate receptors in mediating dual signal transduction activation. J Biol Chem 1998; 273:5615-24.
59. Prezeau L, Manzoni O, Homburger V, Sladeczek F, Curry K, Bockaert J. Characterization of a metabotropic glutamate receptor: direct negative coupling to adenylyl cyclase and inhibition of adenylate cyclase activity in striatal slices. J Neurosci Res 1997; 45:841-50.
60. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic recovery of the heart. J Biol Chem 2001; 276:2571-5.
61. Hur EM, Kim KT. G protein-coupled receptor signalling and cross-talk. Achieving rapidity of signal transduction. Trends Pharmacol Sci 2001; 22:368-76.
62. Lin SH, Maiese K. Group I metabotropic glutamate receptors prevent endothelial programmed cell death independent from MAP kinase p38 activation in rat neurons. Neurosci Lett 2002; 298:207-11.
63. Vougalot P, Holzczew L, Woltenholme J, Russell JT, Hyman SE. Metabotropic glutamate receptors and dopamine receptors cooperate to enhance extracellular signal-regulated kinase phosphorylation in striatal neurons. J Neurosci 2005; 25:3763-73.
64. Ferraguti F, Baldani-Guerra B, Corisi M, Nakashima S, Corri C. Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci 1999; 11:2073-82.
65. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 1999; 29:83-120.
66. van Rossum AJ, Kriegstein AR, O'Donnell TF. Postsynaptic Inhibition of Excitatory Neurones by Group 1 mGluR. J Neurosci 2002; 22:8818-27.
67. Choe ES, Wang JQ. Group 1 metabotropic glutamate receptor activation increases phosphorylation of αtSAMP response element-binding protein, Elk-1, and extracellular signal-regulated keratinized in rat dorsal striatum, Brain Res Mol Brain Res 2001; 97:74-85.
68. Choe ES, Wang JQ. Group 1 metabotropic glutamate receptor activation increases phosphorylation of αtSAMP response element-binding protein, Elk-1, and extracellular signal-regulated keratinized in rat dorsal striatum, Brain Res Mol Brain Res 2001; 97:74-85.
117. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity.

116. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes mellitus in midlife and the risk of dementia three decades later. J Neurosci 2003; 23:1941-9.

115. Blumenthal EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765-71.

114. Blumcke I, Behle K, Malitschek B, Kuhn R, Knopfel T, Wolf HK, Wiestler OD. Spinal cord mGlu1a receptors: possible target for amyotrophic lateral sclerosis therapy. Pharmacol Biochem Behav 2005; 80:567-8.

113. Yano M, Hasegawa G, Ishii M, Yamasaki M, Fukui M, Nakamura N, Yoshikawa T. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004; 9:111-6.

112. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections to 2030. Diabetes Care 2004; 27:1047-53.

111. Ceriello A, dello Russo P, Amatruda F, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 1996; 45:471-7.

110. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Mol Neurobiol 2007; 35:25-40.

109. Nakamichi N, Yoshida K, Ishioka Y, Makanga JO, Fukui M, Yoneyama M, Kitayama T, Sakita H, Kato S, Sato O, Kuriyama S. Suppresses self-replication of undifferentiated neocortical progenitor cells. J Neurochem 2005; 95:450-60.

108. Hu D, Cao K, Peterson-Wakeman R, Wang R. Altered profile of gene expression in rat hearts induced by chronic nicotine consumption. Biochem Biophys Res Commun 2002; 296:317-32.

107. Gillard SE, Tzaferis J, Tsui HC, Kingston AE. Expression of metabotropic glutamate receptors in rat meningeal and brain microvasculature and choroid plexus. J Comp Neurol 2003; 461:317-32.

106. Blumcke I, Behle K, Malitschek B, Kuhn R, Knopfel T, Wolf HK, Wiestler OD. Down’s syndrome brains. Acta Neuropathol (Berl) 1999; 97:275-8.

105. Tang H, Wu LJ, Zhang F, Zhuo M. Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J Neurosci 2008; 28:4835-97.

104. Wang S, Cao K, Peterson-Wakeman R, Wang R. Altered profile of gene expression in rat hearts induced by chronic nicotine consumption. Biochem Biophys Res Commun 2002; 296:317-32.

103. Reid SN, Daw NW, Gregory DS, Flavin H. cAMP levels increased by activation of metabotropic receptors on cultured cerebral endothelial cells. J Neurosci Res 1998; 54:814-9.

102. Anneser JM, Chahli C, Borasio GD. Protective effect of metabotropic glutamate receptor subtype 3A activation on amyotrophic lateral sclerosis-cerebrospinal fluid toxicity in vitro. Neurosci 2006; 141:1879-86.

101. Geurts JJ, Wolswijk G, Bo L, Redeker S, Troost D, Aronica E. Expression patterns of Group III metabotropic glutamate receptors mGluR4 and mGluR8 in multiple sclerosis lesions. J Neuroimmunol 2005; 158:182-90.

100. Nomura A, Shigemoto R, Nakamura Y, Okamoto N, Mizuno N, Nakanishi S. Developmentally regulated postsynaptic localization of a metabotropic glutamate receptor in rat brain cells. Cell 1994; 77:361-9.

99. Nakamura N, Taniura H, Yoneda Y. Group III metabotropic glutamate receptor activation alters protein kinase C activity in rat cerebellum. J Neurosci Res 1998; 54:523-5.

98. Gill SS, Pulido OM, Muiller-PW, McGuire PE. Immunohistochemical localization of the metabotropic glutamate receptors in the rat brain. Brain Res Bull 1999; 48:143-6.

97. Maiese K, Chong ZZ, Kang J. Transformation into treatment: Novel therapies that begin within the cell. In: Neuronal and Vascular Plasticity: Elucidating Basic Cellular Mechanisms for Future Therapeutic Discovery Maiese, K, Ed. Kluwer Academic Publishers: Norwell, MA 2003:1-26.

96. Gill SS, Pulido OM, Muiller-PW, McGuire PE. Immunohistochemical localization of the metabotropic glutamate receptors in the rat brain. Brain Res Bull 1999; 48:143-6.

95. Nakamichi N, Yoshida K, Ishioka Y, Makanga JO, Fukui M, Yoneyama M, Kitayama T, Sakita H, Kato S, Sato O, Kuriyama S. Suppresses self-replication of undifferentiated neocortical progenitor cells. J Neurochem 2005; 95:450-60.

94. Alcañiz IA, Dela V, Menstanzac A, Sildos L, Szabo CA, Andras I, Jou F. Expression of glutamate receptors on cultured cerebral endothelial cells. J Neurosci Res 1998; 54:814-9.

93. Reid SN, Daw NW, Gregory DS, Flavin H. cAMP levels increased by activation of metabotropic glutamate receptors correlate with visual plasticity. J Neurosci 1996; 16:7619-26.

92. Krizbai IA, Dela V, Menstanzac A, Sildos L, Szabo CA, Andras I, Jou F. Expression of glutamate receptors on cultured cerebral endothelial cells. J Neurosci Res 1998; 54:814-9.

91. Blumcke I, Behle K, Malitschek B, Kuhn R, Knopfel T, Wolf HK, Wiestler OD. Down’s syndrome brains. Acta Neuropathol (Berl) 1999; 97:275-8.

90. Wang H, Wu LJ, Zhang F, Zhuo M. Roles of calcium-stimulated adenylyl cyclase and calmodulin-dependent protein kinase IV in the regulation of FMRP by group I metabotropic glutamate receptors. J Neurosci 2008; 28:4835-97.

89. Valerio A, Ferrarini M, Paternini M, Liberini P, Moretto G, Cairns NJ, Pizzi M, Spino P. Spinal cord mGlu1a receptors: possible target for amytrophic lateral sclerosis therapy. Pharmacol Biochem Behav 2005; 82:567-8.

88. Anneser JM, Chahli C, Borasio GD. Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosis-cerebrospinal fluid toxicity in vitro. Neurosci 2006; 141:1879-86.

87. Wong RK, Bianchi R, Chuang SC, Merlin LR. Group I mGluR-induced Epileptogenesis: Distinct and Overlapping Roles of mGluR1 and mGluR5 and Implications for Antiepileptic Drug Design. Epilepsy Curr 2005; 5:63-8.

86. Tang FR, Lee WL. Expression of the group II and III metabotropic glutamate receptors in the hippocampus of patients with mesial temporal lobe epilepsy. J Neurocytol 2001; 30:137-43.

85. Tang FR, Lee WL, Yang J, Sim MK, Ling EA. Metabotropic glutamate receptor 8 in the rat hippocampus after pilocarpine induced status epilepticus. Neurosci Lett 2001; 297:79-36.

84. Blanco VM, Sterin JE, Filosa JA. Tone-dependent vascular responses to acetylcholine-derived signals. Am J Physiol Heart Circ Physiol 2008; 294:H2855-63.

83. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007; 14:1729-38.

82. Maiese K, Moran SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurol Neurosci Rep 2007; 7:463-5.

81. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections to 2030. Diabetes Care 2004; 27:1047-53.

80. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001; 249:225-35.

79. Dabelea D, Bell RA, D’Agostino RB, Jr., Imperatore G, Johansen JM, Linder B, Liu LL, Loon B, Marcovina S, Mayer-Davis EJ, Perrin DJ, Wathenfield B. Incidence of diabetes in youth in the United States. JAMA 2007; 297:2716-24.

78. Jacobson AM, Muesen G, Ryan CM, Silvers N, Clancy P, Wabercki B, Burwood A, Weiner K, Baysles M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842-52.

77. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765-75.

76. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Rev Cardiovasc Ther 2008; 6:281-4.

75. Schmitz M, Fullwood SD, Sileus JL. Changes in metabotropic glutamate receptor expression following spinal cord injury. Exp Neurol 2001; 170:244-57.
Promises and principles for metabotropic receptors

144. Anneser JM, Berthele A, Boratos GD, Castro-Lopes JM, Ziegler-Marschner W, Tolle TR. Anatomy of the sacral nerve directly affects expression of metabotropic glutamate receptor mRNAs in the male mouse. J Neurochem 2000; 74:159-68.

145. Sanchez-Pernaute R, Wang JQ, Kuruppu D, Cao L, Tiekcoumte W, Kozikowski A, Iacson O, Brownell AL. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 2008; 42:248-51.

146. Shen KZ, Johnson SW. A slow excitatory post synaptic current mediated by G-protein-coupled metabotropic glutamate receptors in rat ventral tegmental dopaminergic neurons. Eur J Neurosci 2007; 25:357-9.

147. Campussano JM, Abarca J, Forray MI, Cykling S, Bustos G. Modulation of dendritic release of dopamine by metabotropic glutamate receptors in rat substantia nigra. Biochem Pharmacol 2002; 63:1343-52.

148. Shimazoe T, Dong CH, Arai I, Yoshimatsu A, Fukumoto T, Watanabe S. Both metabotropic glutamate I and II receptors mediate augmentation of dopamine release from the striatum in mouseamphetamine-sensitive rats. Jpn J Pharmacol 2002; 89:85-9.

149. Sarasaeni P, Oja SS. Metabotropic glutamate receptors modulate GABA release from mouse hippocampal slices. Neurochem Res 2001; 26:175-80.

150. Agari T, Yasuhara T, Masui T, Kuramoto S, Kondo A, Miyoshi Y, Shingo T, Borlongan CV, Dair I. Intraperadiall metabotropic glutamate receptor activation in a rat model of Parkinson's disease: behavioral and histological analyses. Brain Res 2008; 1203:189-96.

151. Aham W, Hubert GW, Smith Y, Levey AI, Conn PJ. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 2000; 20:7871-9.

152. Bradley SR, Marino MJ, Wittmann M, Rose ST, Aham W, Levey AI, Conn PJ. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. J Neurosci 2000; 20:3085-94.

153. Wolfaarth S, Konieczny J, Lorenz-Koci E, Ossowska K, Pilc A. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 2000; 19:95-101.

154. Dawson L, Chadha A, Megalou M, Dury S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br J Pharmacol 2000; 129:541-6.

155. Mataredona ER, Santiago M, Venero JL, Cano J, Machado A. Group II metabotropic glutamate receptors during anoxia and nitric oxide toxicity. J Neurochem 1996; 66:2419-27.

156. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

157. Rytomaa M, Lehmann K. Downward J. Matrix detachment induces caspase-dependent cytotoxicity and release of mitochondrial cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling. Oncogene 2000; 19:4461-8.

158. Namikawa K, Honma A, Abe T, Takeda M, Mansur K, Ohta T, Miwa A, Okado H, Kiyama H. Akt/protein kinase B inhibits injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 2000; 20:2875-86.

159. Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F, Heumann R, Anttonen P, Krutz B, Bittigau P, Thor F, Heumann R, Anttonen P, Kirsch I, Schroder K, Zwicker J, Werner R, Kusske W, Scharf G, Albrecht T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D. Low-dose erythropoietin protects the developing brain from MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurosci Res 2005; 2:425-46.

160. Chong ZZ, Li F, Maiese K. Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

161. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

162. Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F, Heumann R, Anttonen P, Krutz B, Bittigau P, Thor F, Heumann R, Anttonen P, Kirsch I, Schroder K, Zwicker J, Werner R, Kusske W, Scharf G, Albrecht T, de Groot K, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D. Low-dose erythropoietin protects the developing brain from MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurosci Res 2005; 2:425-46.

163. Chong ZZ, Li F, Maiese K. Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

164. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

165. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

166. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

167. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.

168. Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G. Iptakalim hydrochloride therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3:107-17.
198. Miki T, Miura T, Yano T, Takashashi A, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Nishihara M, Naitoh K, Ohori K, Shimamoto K. Alteration in erythropoietin-induced car- dioprotective signaling by point mutation ventricular remodeling. J Pharmacol Exp Ther 2006; 317:68-75.

199. Parsa CJ, Matsuno A, Kim J, Riel RL, Dass LS, Walton GB, Thompson RB, Pernofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112:999-1007.

200. Sharpe JD, Perdel J, Vassilev V, Katsalidis P, Reinhard C, Latz E. Programming of cell death by myeloid factors during sepsis. J Immunol 2008; 180:2357-65.

201. Um M, Gross AW, Lodish HF. A “classical” homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and primary SH-SY5Y neural cells. J Biol Chem 2007; 282:9394-5.

202. Um M, Lodish HE. Antiproteolytic Effects of Erythropoietin in Differentiated Neuroblastoma SH-SY5Y Cells Require Activation of Both the STAT5 and Akt Signaling Pathways. J Biol Chem 2006; 281:5648-56.

203. Wu Y, Shang Y, Sun S, Liu R. Antioxidant effect of erythropoietin on 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cells. Eur J Pharmacol 2007; 546:47-56.

204. Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andreu TH. The inhibition of glycogen synthase kinase 3beta by a metabolic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem 2005; 95:1363-72.

205. Rong R, Ahn JY, Huang H, Nagata E, Kalman D, Kapp JA, T u J, Worley PF, Snyder SH, Ye K. PI3 kinase enhancer- Homer complex couples mGluR1 to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci 2003; 6:1153-61.

206. Maiese K, Vincent AM, Group I metabolic receptors down-regulate nitric oxide induced caspase-3 activity in rat hippocampal neurons. Neurosci Lett 1999; 264:17-20.

207. Hou L, Klann E. Activation of the phosphoinositol 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabolic glutamate receptor-dependent long-term depression. J Neuroscience 2004; 24:6352-61.

208. Ronesi JA, Huber KM. Homer interactions are necessary for metabolic glutamate recep- tor-induced long-term depression and translational activation. J Neuroscience 2008; 28:5437-7.

209. Xu W, Wong TP, Chery N, Guertner T, Wang YT, Baudry M. Calpain-mediated mGluR1Al- pha truncation: a key step in excitotoxicity. Neuron 2007; 53:399-412.

210. Maiese K, Boniece I, DeMeo D, Wagner JA. Peptide growth factors protect against ischemia-induced apoptosis. J Neurosci 2006; 26:6265-78.

211. Vianna MR, Coitinho AS, Izquierdo I. Role of the hippocampus and amygdala in the extinction of fear-motivated learning. Curr Neurovasc Res 2004; 1:55-60.

212. Szapiro G, Izquierdo LA, Alonso M, Barros D, Paratcha G, Ardenghi P, Pereira P, Medina JH, Izquierdo I. Participation of hippocampal metabotropic glutamate receptors, protein kinase A and mitogen-activated protein kinases in memory retrieval. Neuroscience 2000; 93:251-60.

213. Szapiro G, Izquierdo LA, Alonso M, Barros D, Paratcha G, Ardenghi P, Pereira P, Medina JH, Izquierdo I. Participation of hippocampal metabotropic glutamate receptors, protein kinase A and mitogen-activated protein kinases in memory retrieval. Neuroscience 2000; 93:251-60.

214. Sugiyama Y, Kawaguchi SY, Hirano T. mGluR1-mediated facilitation of long-term potentiation (LTP) in the CA1 region of the hippocampus. J Neurosci 2004; 24:776-86.

215. Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against reactive oxygen species-induced apoptosis. Mol Cell Endocrinol 2007; 281(1-2):47-55.

216. Groth U, Henderson C, Pettmann B. Foxo3a regulates mouse heart development through the Fox pathway in cooperation with JNK. BMC Neurosci 2004; 5:48.

217. Chong ZZ, Shang YC, Alberi I, Lucangelo J, Anderson A, Auburger P, Deckert M. Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene 2003; 22:4557-68.

218. Li P, Nijhawan D, Bhardwaj I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1-caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89.

219. Zhao L, Quan ZM, Zhang C, Wang HY, Du F, Xu Y. Amyloid beta-peptide 31-35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. Aging Cell 2008; 7:47-57.

220. Maiese K. Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother 2008; 62:218-32.

221. Chong ZZ, Li P, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt and canonical signaling pathways. Cell Signal 2007; 19:1150-62.

222. Smith WW, Norton DD, Gotope M, Jiang H, Nemoto S, Holbrook NJ, Finkel T, Kusiak K. P66Shc and forkhead proteins mediate Abeta toxicity. J Cell Biol 2005; 169:319-31.

223. Hoogenboom D, Essers MA, Polderman PE, Voets T, Smit LM, Burgering BM. Interaction of FOXO3a with [beta]-Catenin Inhibits [beta]-Catenin/T Cell Factor Activity. J Biol Chem 2006; 281:9224-30.

224. Adachi K, Mirzadeh Z, Sakaguchi M, Yamashita T, Nikolcheva T, Gotoh Y, Petz L, Gong L, Kawase T, Alvarez-Buylla A, Okano H, Sawamoto K. beta-Catenin signaling promotes proliferation of progenitor cells in the adult mouse subventricular zone. Stem Cells 2007; 25:2827-36.

225. Wester EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 2007.

226. Castelo-Branco G, Rawal N, Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci 2004; 117:5731-7.

227. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosamond J, Madeddu P, Emanueli C. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxida- tion. Proc Natl Acad Sci USA 1999; 96:7421-6.

228. Chong ZZ, Shang YC, Alberi I, Lucangelo J, Anderson A, Auburger P, Deckert M. Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene 2003; 22:4557-68.

229. Harwood S, Raftery M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against reactive oxygen species-induced apoptosis. Mol Cell Endocrinol 2007; 281(1-2):47-55.

230. Nakamura T, sakamoto K. Forkhead transcription factor FOXO subfamily is essential for survival during oxidative stress through protein kinase b coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab 2004; 24:728-43.

231. Oheus E, Geiger K, Ambros P, Meister B, Ausserlechner MJ. FKHR1-mediated expres- sion of Nono and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 2007; 14:439-54.

232. Barthelmy C, Henderson CE, Pettmann B. Foxo3a mediates mouse heart death through the Fox pathway in cooperation with JNK. BMC Neurosci 2004; 5:48.

233. You H, Yamamoto K, Mak TW. Regulation of translation-inactivation dependent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A 2006; 103:9551-6.

234. Caporali A, Sala-Newby GB, Meloni M, Graiani G, Pani E, Cristofaro B, Newby AC, Madeddu P. FoxO1 and FOXO3a regulates glucose metabolism and enhances lactate production in the ruminant kidney. J Clin Invest 2006; 117:3043-56.

235. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Yeoh K, Maden M, Zandi P, Shoturma D, Ilett KF, Eizirik DL, Rivier J, Friesen HG. FoxO1 and FOXO3a regulates glucose metabolism and enhances lactate production in the ruminant kidney. J Clin Invest 2006; 117:3043-56.

236. Ando F, Suzuki N, Araki H, Ouchi T, Inoue T, Shimamoto K, Kubo Y. Angiotensin II receptor blockade induces FoxO3a phosphorylation and nuclear translocation in granule neurons. J Neurochem 2007; 104:62-73.

237. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and mainte- nance. Curr Opin Neurobiol 2000; 10:392-9.
255. Slusarski DC, Corces VG, Moon RT. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997; 390:410-3.

256. Ma L, Wang HY. Suppression of cyclic GMP-dependent protein kinase is essential to the Wnt/GMP/Ca^2+ pathway. J Biol Chem 2006; 281:30990-1001.

257. Schulte G, Bryja V. The Frizzled family of unconventional G-protein-coupled receptors. Trends Pharmacol Sci 2007; 28:518-25.

258. Spitzer NC, Olson E, Gu X. Spontaneous calcium transients regulate neuronal plasticity in developing neurons. J Neurobiol 1995; 26:316-24.

259. Zirpel L, Janowski MA, Taylor DA, Parks TN. Developmental changes in metabotropic glutamate receptor-mediated calcium homeostasis. J Comp Neurol 2008; 421:95-106.

260. Endoh T. Characterization of modulatory effects of postsynaptic metabotropic glutamate receptors on calcium currents in rat nucleus tractus solitarius. Brain Res 2004; 1024:212-24.

261. Haak LL. Metabotropic glutamate receptor modulation of glutamate responses in the suprachiasmatic nucleus. J Neurophysiol 1999; 81:1308-17.

262. Zur Nieden R, Deitmer JW. The Role of Metabotropic Glutamate Receptors for the Generation of Calcium Oscillations in Rat Hippocampal Astrocytes In Situ. Cereb Cortex 2005.

263. Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliveira-Emilio HC, Carpinelli AR, Curi R. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583:9-24.

264. Lin SH, Chong ZZ, Maiese K. The metabotropic glutamate receptor system: G-Protein mediated pathways that modulate neuronal and vascular cellular injury. Curr Med Chem -Central Nervous System Agents 2002; 2:17-28.

265. Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999; 160:226-34.

266. Vincent AM, Maiese K. The metabotropic glutamate receptor system promotes neuronal survival through distinct pathways of programmed cell death. Exp Neurol 2000; 166:65-82.

267. Luyt K, Varadi A, Durant CF, Molnar E. Oligodendroglial metabotropic glutamate receptors are developmentally regulated and involved in the prevention of apoptosis. J Neurochem 2006; 99:641-56.

268. Pshenichkin S, Dolinska M, Klauzinska M, Luchenko V, Grajkowska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor 1 in conditions of trophic deprivation - Possible role as a dependence receptor. Neuropharmacology 2008.

269. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 2001; 98:6951-6.

270. Abraham KE, McGinty JF, Brewer KL. The role of kainic acid/AMPA and metabotropic glutamate receptors in the regulation of opioid mRNA expression and the onset of pain-related behavior following excitotoxic spinal cord injury. Neuroscience 2001; 104:863-74.

271. Fundytus ME, Yashpal K, Chabot JG, Osborne MG, Lefebvre CD, Dray A, Henry JL, Codere T. Knockdown of spinal metabotropic glutamate receptor 1 (mGluR1)) alleviates pain and restores opioid efficacy after nerve injury in rats. Br J Pharmacol 2001; 132:554-67.

272. Pellegri-Giampietro DE, Peruginelli F, Meli E, Cozzi A, Albani-Tortregrossa S, Pellicciari R, Moroni F. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropsychopharmacology 1999; 18:1607-19.

273. Shuaib A, Kanthan R. Amplification of inhibitory mechanisms in cerebral ischemia: an alternative approach to neuronal protection. Histol Histopathol 1997; 12:185-94.

274. Beyssy N, Baurer C, Spooner W, Gasparini F, Amltic M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 2002; 22:5669-78.